Association Between Insulin Resistance Marker Estimated Glucose Disposal Rate and Cardiovascular Risk in Obesity: Insights From the National Health and Nutrition Examination Survey 1999 to 2018
Related Experiment Video
Updated: Jul 5, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Xu Hua1, Hai Nan Yang1, Yao Guo Han1
1Department of Critical Care Medicine, Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Pudong New District, Shanghai 200137, China.
Background:
This study evaluated the effectiveness of the estimated glucose disposal rate (eGDR), an indicator of insulin resistance, as a screening tool for cardiovascular disease (CVD) in individuals with obesity.
Methods:
A cross-sectional analysis was conducted using data from the US National Health and Nutrition Examination Survey (NHANES) covering the years 1999 to 2018. The study included 20,521 participants with a waist-to-height ratio (WHtR) of 0.6 or higher, indicating obesity. Participants were divided into quartiles based on their eGDR levels: Q1 (> 8 mg/kg/min), Q2 (6 - 8 mg/kg/min), Q3 (4 - 6 mg/kg/min), and Q4 (≤ 4 mg/kg/min). Multivariable logistic regression models, adjusted for various demographic, lifestyle, and metabolic confounders, were used to analyze the relationship between eGDR and CVD. The predictive capability of eGDR was assessed using the area under the receiver operating characteristic curve (AUC), restricted cubic splines (RCS) for capturing non-linear relationships, and stratified subgroup analyses.
Results:
CVD prevalence significantly increased with decreasing eGDR levels (Q1: 5.3% vs. Q4: 26.2%). After full adjustment for covariates, multivariable regression confirmed that the lowest eGDR quartile (Q4) was strongly and independently associated with a substantially elevated risk of CVD compared to the highest quartile (adjusted odds ratio (OR) = 6.3; 95% confidence interval (CI): 5.53 - 7.17; P < 0.001). eGDR also demonstrated good predictive performance for specific CVD subtypes, with the highest AUC for heart failure (0.715, 95% CI: 0.699 - 0.730). RCS analysis validated a significant non-linear, inverse dose-response relationship between eGDR and overall CVD risk. Subgroup analyses, stratified by age, sex, and glycemic status, consistently demonstrated a significant association between low eGDR and increased CVD risk across all categories (P < 0.001).
Conclusions:
Lower eGDR independently and strongly indicated a heightened risk of CVD in individuals with obesity.
More Related Videos
08:30Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
Published on: March 15, 2018
06:13Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
Published on: December 1, 2023
Related Concept Videos
Obesity
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Coronary Artery Disease I: Introduction
Type II Diabetes I: Introduction